• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <0.01 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit proliferation of HeLa human cervical epithelial carcinoma cells. Ko, L.     et al. (2002) Exp. Cell Res.     280:280. The ED    ₅₀ for this effect is 0.05-0.25 μg/mL.

• Source

  Mouse myeloma cell line, NS0-derived Ala33-Asn325

• Accession #

• N-terminal Sequence    
  Analysis

  Ala33

• Predicted Molecular Mass

  33.2 kDa

• SDS-PAGE

  39 kDa, reducing conditions

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: sFRP-3

Secreted Frizzled Related Protein‑3 (sFRP‑3), also known as FRZB, belongs to a family of Wnt-binding proteins with homology to the ligand‑binding domain of the Frizzled receptors. sFRPs are approximately 30‑35 kDa in size and contain an N‑terminal Frizzled‑like domain with 10 conserved cysteines and a Netrin-like C‑terminal domain (1‑4). Mature human sFRP‑3 shares 93% aa sequence identity with mouse and rat sFRP‑3. It neutralizes the bioactivity of Wnt‑1, ‑5a, ‑9a, Xenopus Xwnt‑8, and EGF (5‑8). sFRP‑3 regulates somitic myogenesis and osteoblast differentiation as well as morphogenesis of the cochlear epithelium, hair follicle, and cardiac atrioventricular cushion (6, 8‑10). sFRP‑3 also functions as a tumor suppressor in a variety of cancers including melanoma, medulloblastoma, soft tissue sarcoma, and androgen‑independent prostate cancer. It inhibits epithelial-mesenchymal transition, tumor growth and invasion, and the activity of MMP‑2 and MMP‑9 (7, 11‑13). In contrast, it can promote tumor growth and angiogenesis in renal cancer (14).

• References:

1. Bovolenta, P. et al. (2008) J. Cell Sci. 121:737.

2. van Amerongen, R. and R. Nusse (2009) Development 136:3205.

3. Rattner, A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2859.

4. Hoang, B. et al. (1996) J. Biol. Chem. 271:26131.

5. Wang, S. et al. (1997) Cell 88:757.

6. Person, A.D. et al. (2005) Dev. Biol. 278:35.

7. Ekstrom, E.J. et al. (2011) PLoS ONE 6:e18674.

8. Scardigli, R. et al. (2008) PLoS ONE 3:e2471.

9. Qian, D. et al. (2007) Dev. Biol. 306:121.

10. Chung, Y.-S. et al. (2004) J. Bone Miner. Res. 19:1395.

11. Kongkham, P.N. et al. (2010) Oncogene 29:3017.

12. Guo, Y. et al. (2008) Cancer Res. 68:3350.

13. Zi, X. et al. (2005) Cancer Res. 65:9762.

14. Hirata, H. et al. (2010) Cancer Res. 70:1896.

• Long Name:

  Secreted Frizzled Related Protein 3

• Entrez Gene IDs:

  2487 (Human); 20378 (Mouse)

• Alternate Names:

  FIZ; FREOS1; Frezzled; Fritz; Frizzled-related protein 1; frizzled-related protein; FRP; FRP-3; FRZB; Frzb1; FRZB-1; FRZB1sFRP-3; FRZB-PEN; FZRB; hFIZ; secreted frizzled-related protein 3; sFRP3; sFRP-3; SFRP3frezzled; SRFP3frizzled homolog-related